ReviewLung cancer (Amsterdam, Netherlands)2011
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Review in Lung cancer (Amsterdam, Netherlands), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.Molecular & cellular proteomics : MCP · 2013Trial
- First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial.British journal of cancer · 2012Trial
- Case Report: A case of femoral metastatic cancer misdiagnosed as isolated femoral lesser trochanter avulsion fracture.Frontiers in oncology · 2025Article
- MesoGraph: Automatic profiling of mesothelioma subtypes from histological images.Cell reports. Medicine · 2023Article
- Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.Frontiers in oncology · 2023Article
- Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.Translational lung cancer research · 2021Article
- Inhibitors of cytoskeletal dynamics in malignant mesothelioma.Oncotarget · 2020Article
- Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.International journal of molecular sciences · 2019Article
- Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.Oncotarget · 2019Article
- Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.Journal of oncology · 2019Article
- Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response.Cancer management and research · 2019Article
- Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.Advances in respiratory medicine · 2019Review
- New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.Scientific reports · 2018Article
- A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.World journal of surgery · 2018Article
- Article
- Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.Journal of oncology · 2018Article
- Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.Journal of gastrointestinal oncology · 2017Review
- miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.Virchows Archiv : an international journal of pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The global burden of mesothelioma is expected to increase in the coming decades. As a result the development of more effective therapies with an emphasis on personalized treatments based on validated prognostic and predictive biomarkers is an essential requirement. Progress has been made in the last decade with the development of newer generation anti-folates leading to the current standard of care of pemetrexed and cisplatin in patients with unresectable disease. However, the median overall survival of patients with this combination treatment is only 12 months. There is no consensus regarding second line therapy for patients who have progressed or not responded to pemetrexed based therapies although gemcitabine in combination with a platinum compound or single agent vinorelbine is a reasonable option. The development of effective targeted agents that are active in mesothelioma has to date been disappointing. Strategies involving the addition of bevacizumab to pemetrexed and cisplatin in the frontline setting, the histone deacetylase inhibitor vorinostat as second line therapy and studies evaluating the utility of maintenance therapy in mesothelioma are all ongoing and appear promising. In addition clinical trials investigating immunotherapy and gene therapy in combination with chemotherapy could potentially improve the prognosis of patients with mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.